722 Stock Overview
A biopharmaceutical company, develops novel oncology therapies in Greater China and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Antengene Corporation Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$0.40 |
| 52 Week High | HK$0.46 |
| 52 Week Low | HK$0.025 |
| Beta | 0.99 |
| 1 Month Change | 44.29% |
| 3 Month Change | 128.25% |
| 1 Year Change | 316.49% |
| 3 Year Change | -47.94% |
| 5 Year Change | n/a |
| Change since IPO | -77.30% |
Recent News & Updates
Recent updates
Shareholder Returns
| 722 | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 27.0% | -6.6% | 1.1% |
| 1Y | 316.5% | -25.3% | 16.0% |
Return vs Industry: 722 exceeded the German Pharmaceuticals industry which returned -27.3% over the past year.
Return vs Market: 722 exceeded the German Market which returned 15% over the past year.
Price Volatility
| 722 volatility | |
|---|---|
| 722 Average Weekly Movement | 17.6% |
| Pharmaceuticals Industry Average Movement | 5.8% |
| Market Average Movement | 6.6% |
| 10% most volatile stocks in DE Market | 12.8% |
| 10% least volatile stocks in DE Market | 3.1% |
Stable Share Price: 722's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 722's weekly volatility has decreased from 27% to 18% over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2017 | 169 | Jay Mei | www.antengene.com |
Antengene Corporation Limited, a biopharmaceutical company, develops novel oncology therapies in Greater China and internationally. Its commercialized assets include ATG-010 (selinexor), an oral SINE compound for the treatment of various hematological malignancies and solid tumors comprising relapsed/refractory multiple myeloma (rrMM), relapsed/refractory diffuse large B-cell lymphoma, and multiple myeloma (MM) in adult patients. Its late-stage products candidates comprise ATG-008 (onatasertib), an mTOR inhibitor for the treatment of cervical cancer and other advanced solid tumors.
Antengene Corporation Limited Fundamentals Summary
| 722 fundamental statistics | |
|---|---|
| Market cap | €286.26m |
| Earnings (TTM) | -€39.20m |
| Revenue (TTM) | €11.29m |
Is 722 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 722 income statement (TTM) | |
|---|---|
| Revenue | CN¥91.95m |
| Cost of Revenue | CN¥17.78m |
| Gross Profit | CN¥74.17m |
| Other Expenses | CN¥393.42m |
| Earnings | -CN¥319.25m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.47 |
| Gross Margin | 80.66% |
| Net Profit Margin | -347.20% |
| Debt/Equity Ratio | 28.2% |
How did 722 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/20 09:50 |
| End of Day Share Price | 2025/05/20 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Antengene Corporation Limited is covered by 6 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Ziyu He | China International Capital Corporation Limited |
| Wangbin Zhou | Citigroup Inc |
| null null | CMB International Securities Limited |